Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

multiple sclerosis drug

This page shows the latest multiple sclerosis drug news and features for those working in and with pharma, biotech and healthcare.

J&J’s MS drug ponesimod receives approval in the US

J&J’s MS drug ponesimod receives approval in the US

Johnson &Johnson’s (J&J) pharma division Janssen has announced that the US Food and Drug Administration (FDA) has approved its multiple sclerosis (MS) treatment ponesimod, under the brand name Ponvory. ... Every person with multiple sclerosis is

Latest news

  • FDA advisory committee overwhelmingly votes no on Biogen's aducanumab FDA advisory committee overwhelmingly votes no on Biogen's aducanumab

    Path to approval looks increasingly difficult for potential Alzheimer’s treatment. A panel of outside experts met on Friday to examine data supporting Biogen’s new drug application for its potential ... spinal muscular atrophy drug Spinraza

  • Biogen triumphs over Mylan’s Tecfidera patent challenge Biogen triumphs over Mylan’s Tecfidera patent challenge

    Shares in Biogen skyrocketed by 32% following ruling. Biogen has scored its first major success of the year, winning a patent challenge from Mylan over its multiple sclerosis drug Tecfidera.  . ... The dispute was a significant one for Biogen –

  • Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

    BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to ... $94m. Meanwhile, Caforio is confident that

  • Cosentyx, Entresto drive topline growth for Novartis in Q4 Cosentyx, Entresto drive topline growth for Novartis in Q4

    Following Cosentyx was Entresto, which grew by 71% in Q4 to $1.7bn, an impressive increase from the $430m Novartis posted for the drug in Q3. ... Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer

  • Biogen under fire over $88,000 Vumerity annual price Biogen under fire over $88,000 Vumerity annual price

    Pricing pressure levelled at Tecfidera follow-up MS drug. Biogen has been criticised for the price of its next-generation multiple sclerosis drug Vulmerity, after pricing it at $88, 000 for ... patients who are stable on Tecfidera will be unwilling to to

More from news
Approximately 0 fully matching, plus 145 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The key difference between DS-8201

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee. ... The company has just secured 'Rapid Uptake' status for its multiple sclerosis drug Mavenclad via the new Accelerated Access Collaborative process

  • Death by Numbers Death by Numbers

    Not so. Take the example of this campaign for Sativex, a drug used in the treatment of Multiple Sclerosis.

  • A new dogma in HTA assessment A new dogma in HTA assessment

    Novartis faced similar difficulties in the UK when its multiple sclerosis drug Gilenya was declined by the National Institute for Health and Clinical Excellence (NICE) due to its comparator, Avonex, not ... High-end scenario planning capabilities will

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis

  • Michael Fleming joins biosimilars firm Coherus Michael Fleming joins biosimilars firm Coherus

    of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept). ... Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Covid-19: how is it affecting prescribing patterns?

    In this article, we will examine three key disease areas: COPD, rheumatoid arthritis and multiple sclerosis to determine which drug types have been the winners and losers in terms of usage ... Multiple sclerosis. Multiple sclerosis presents a more

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....

Quick links